Document:

EXHIBIT
10.36

     

    STOCK
OPTION AGREEMENT

    AND

    NOTICE
OF GRANT

    

    Date of
Grant: January 21, 2009

     

    Anthony
Giordano, III

    c/o
Central Jersey Bank

    1903
Highway 35

    Oakhurst,
New Jersey  07755

    

    Dear
Anthony:

     

    In
recognition of your continued service to Scivanta Medical Corporation
(“Scivanta”) and to encourage you to continue to take into account the long-term
interests of Scivanta, the Board of Directors of Scivanta (the “Board”) has
authorized the grant to you of an option (the “Option”) to purchase thirty-nine
thousand (39,000) shares (the “Shares”) of Scivanta’s common stock, par value
$.001 per share (“Common Stock”), under the Scivanta Medical Corporation 2007
Equity Incentive Plan (the “Equity Incentive Plan”).

     

    1.           Equity Incentive
Plan.

     

    The
Option is a Nonqualified Option and subject to each and every provision of the
Equity Incentive Plan which are incorporated by reference herein, as well as the
terms and provisions set forth in this Stock Option Agreement and Notice of
Grant (this “Stock Option Agreement”).  The Equity Incentive Plan
shall govern and be conclusive as to all matters not expressly provided for in
this Stock Option Agreement.  In the event of any conflict between the
terms of this Stock Option Agreement and the Equity Incentive Plan, the terms of
this Stock Option Agreement shall govern.  All capitalized terms
contained herein which are not otherwise defined herein shall have the meanings
ascribed to them in the Equity Incentive Plan.  By accepting the
Option you agree to be bound by the provisions of the Equity Incentive Plan and
this Stock Option Agreement.  A copy of the Equity Incentive Plan has
been previously provided to you.

     

    2.           Exercise Price and
Procedure.

     

    The per
share exercise price of the Option is $0.14 (the “Option Price”), which is equal
to the closing price of Scivanta’s Common Stock on January 21,
2009.  The Option Price may be adjusted as provided for in the Equity
Incentive Plan.  Full payment shall be made for any Shares to be
purchased under the Option at the time of exercise of the
Option.  Payment for the Shares to be purchased upon the exercise of
the Option shall be made by personal check or in cash in an amount equal to the
aggregate Option Price.  Alternatively, payment for the Shares to be
purchased upon the exercise of the Option may be made by (a) delivery of a
number of shares of Common Stock owned by you which have an aggregate Fair
Market Value equal to or greater than the aggregate Option Price, or (b)
instructing Scivanta to withhold from the Shares deliverable upon exercise of
the Option that number of Shares which have an aggregate Fair Market Value equal
to or greater than the aggregate Option Price.  The portion of any
payment in the form of Common Stock which exceeds the aggregate Option Price,
will be returned to you in the form of a cash payment.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    Subject
to the terms of this Stock Option Agreement and the Equity Incentive Plan, the
Option shall become exercisable on the date or dates, and subject to such
conditions, as are set forth herein.  To the extent that a portion of
the Option is or becomes exercisable and is not exercised, such portion shall
accumulate and be exercisable by you in whole or in part at any time prior to
expiration of the Option, subject to the terms of this Stock Option Agreement
and the Equity Incentive Plan.  You expressly acknowledge that the
Option may vest and be exercisable only upon such terms and conditions as are
provided in this Stock Option Agreement and the Equity Incentive
Plan.

     

    To
exercise all or any portion of the Option, you must provide to Scivanta (a)
written notice of such exercise, which is to include the number of Shares of
Scivanta’s Common Stock to be purchased upon such exercise (the “Notice of
Exercise”), and (b) payment of the aggregate Option Price as provided
above.  A form of Notice of Exercise is attached
hereto.  The Notice of Exercise is to be delivered to Scivanta at the
following address:

     

    Scivanta
Medical Corporation

    215
Morris Avenue

    Spring
Lake, New Jersey  07762

    Attn: 
Thomas S. Gifford

    Executive
Vice President,

    Chief
Financial Officer and Secretary

    

    Upon the exercise of the Option in
whole or in part and payment of the aggregate Option Price in accordance with
the provisions of this Stock Option Agreement, Scivanta shall, as soon
thereafter as practicable, deliver to you a certificate or certificates for the
Shares purchased.

     

    3.           Term and
Vesting of Options.

     

    The date
of grant of the Option is January 21, 2009 and the Option shall expire on and
may not be exercised after January 21, 2014 (the “Term”), unless such Term is
reduced or extended as provided for herein or in the Equity Incentive
Plan.

     

    The
Shares of Common Stock underlying the Option vest as follows:  9,750
Shares vest on March 31, 2009; 9,750 Shares vest on June 30, 2009; 9,750 Shares
vest on September 30, 2009; and 9,750 share vest on December 31,
2009.

     

    Unless
the Board determines otherwise, upon your termination as a member of the Board
for any reason whatsoever, including death and Disability, your right to
purchase any Shares underlying the Option which have not vested shall terminate
and be of no further effect.  Any Shares of Common Stock underlying
the Option which have vested at the time you cease to be a member of the Board,
for any reason other than death, shall remain subject to purchase through the
remainder of the Term.

     

    Upon your
death, all vested Shares of Common Stock underlying the Option may be purchased
by the administrator of your estate for a period of one year following your
death.  Your right to purchase any vested Shares of Common Stock
available for purchase under the Option which have not been purchased within one
year from the date of your death, shall automatically terminate on the one year
anniversary of your death and be of no further effect.  In the event
of a Change in Control of Scivanta, the Option becomes fully vested as of ten
days prior to the Change in Control.

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

     

    4.           Miscellaneous.

     

    4.01.   Nonqualified
Option.  The Option is not qualified for favorable tax
treatment under Sections 422 or 423 of the Internal Revenue Code of 1986, as
amended (the “Code”).  Scivanta recommends that you consult with your
tax advisor regarding the tax consequences related to the Option.

     

    4.02.   Restrictions on
Transferability of the Option and Shares.  The Option is not
transferable by you except by will or the laws of descent and
distribution.  The Shares to be acquired by you pursuant to the
exercise of the Option have not been registered under the Securities Act of
1933, as amended, or any state securities act or law, and, as a result, are
subject to certain restrictions on transfer thereunder.

     

    4.03.   Withholding.  As
a condition to the issuance of Shares upon the exercise of the Option, Scivanta
can require you to remit to it the amount which Scivanta has determined must be
withheld in respect of federal or state income attributable to any taxable
income to be recognized by you in connection with the exercise of the
Option.

     

    4.04.   No Right of
Service.  No provision of this Stock Option Agreement or of the
Equity Incentive Plan shall give you any right to continue as a member of the
Board of Scivanta or interfere with the right of Scivanta to terminate your
service as a director at any time in accordance with Scivanta’s Bylaws and
applicable law.

     

    4.05.   Governing Law and
Jurisdiction.  The Equity Incentive Plan and this Stock Option
Agreement shall be construed and their respective provisions enforced and
administered in accordance with the laws of the State of Nevada.

     

    4.06.   Compliance with Code Section
409A.  Notwithstanding any other provision in this Stock Option
Agreement or the Equity Incentive Plan to the contrary, if and to the extent
that Section 409A (“Section 409A”) of the Code is deemed to apply to the Equity
Incentive Plan, this Stock Option Agreement or the Option granted hereby, it is
the general intention of Scivanta that the Equity Incentive Plan, this Stock
Option Agreement and the Option shall comply with Section 409A, related
regulations or other guidance, and the Equity Incentive Plan, this Stock Option
Agreement and the Option shall, to the extent practicable, be construed in
accordance therewith.

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

     

    If you
wish to accept the Option granted hereby pursuant to the terms set forth herein,
please signify your acceptance by countersigning this Stock Option Agreement
below where designated.  Any comments or questions should be directed
to Thomas S. Gifford, Executive Vice President, Chief Financial Officer and
Secretary at Scivanta Medical Corporation, 215 Morris Avenue, Spring Lake, New
Jersey  07762.  The phone number of Scivanta is (732)
282-1620.

     

    
      
        
          
            
              	
                      Very
      truly yours,

                    
	 
      	 
      
	
                      Scivanta
      Medical Corporation

                    
	 
      	 
      
	
                      By:

                    	
                      /s/  Thomas S.
      Gifford

                    
	
                      Name:

                    	
                      Thomas
      S. Gifford

                    
	
                      Title:

                    	
                      Executive
      Vice President, Chief Financial

                    
	 
      	
                      Officer
      and
Secretary

                    

            

          

        

      

    

    

    By the
execution hereof, I accept the grant of Option provided for herein and agree to
be bound by the terms and provisions set forth in this Stock Option Agreement
and the Equity Incentive Plan.

     

    
      
        
          	
                  /s/ Anthony Giordano,
III

                
	
                  Anthony
      Giordano, III

                

        

      

    

     

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

     

    NOTICE
OF EXERCISE

     

    Date:
_______ __, 20__

     

    Scivanta
Medical Corporation

    215
Morris Avenue

    Spring
Lake, New Jersey  07762

    Attention:  Thomas
S. Gifford, Executive Vice President, Chief Financial Officer and
Secretary

     

    Dear Mr.
Gifford:

     

    I hereby
exercise the non-qualified stock option (the “Option”) granted to me on January
21, 2009 for the purchase of ________ shares (the “Shares”) of common stock, par
value $.001 per share (“Common Stock”), of Scivanta Medical Corporation
(“Scivanta”).  I was granted the Option under the Scivanta Medical
Corporation 2007 Equity Incentive Plan (the “Equity Incentive
Plan”).  The per share exercise price is $0.14 (the “Option Price”)
and the aggregate Option Price for the Shares being purchased is
$___________.

     

    Please
check the box next to the applicable payment provision:

     

    
      	
               ̈

            	
              As
      full payment for the Shares being purchased, enclosed with this Notice of
      Exercise is a personal check or cash in the amount of the aggregate Option
      Price of $___________.  (Checks should be made payable
      to “Scivanta Medical
Corporation”.)

            

    

     

    
      	
               ̈

            	
              I
      wish to pay for the Shares being purchased by delivering to Scivanta that
      number of Shares of Common Stock which have an aggregate Fair Market Value
      (as defined in the Equity Incentive Plan) equal to or greater than the
      aggregate Option Price.

            

    

     

    
      	
               ̈

            	
              I
      wish to pay for the Shares being purchased by having Scivanta withhold
      therefrom the number of Shares of Common Stock which have an aggregate
      Fair Market Value equal to or greater than the aggregate Option
      Price.

            

    

     

    I agree
hereby that Scivanta is not required to issue me the Shares to be purchased
pursuant to my exercise of the Option as provided for in this Notice of
Exercise, until I have remitted to Scivanta the aggregate amount of any
applicable withholding taxes which Scivanta has notified me shall be withheld in
connection with the exercise of the Option.

     

    I hereby
understand that the Shares to be acquired by me pursuant to the exercise of the
Option have not been registered under the Securities Act of 1933, as amended, or
any state securities act or law, and, as a result, are subject to certain
restrictions on transfer thereunder.

     

    
      
        
          
            
              
                
                  
                    	 
      
	
                            Signature

                          
	 
      
	 
      
	
                            Print
      Name

                          
	 
      
	 
      
	 
      
	 
      
	
                            Address

                          
	 
      
	 
      
	
                            Tax
      Identification
NumberUnassociated Document

    

    Exhibit
10.1

    Unofficial
Summary Translation

    Assets
Transfer Contract

    

    Party A: Shandong Traditional
Chinese Medicine College

    Party B: The Traditional
Chinese Medicine College of Shandong Hongrui Pharmaceutical Factory

    Party C: Laiyang Jiangbo
Pharmaceutical Co., Ltd.

    

    NOW,
THEREFORE, after friendly negotiations, Party A, B, and C reach the following
agreements on Party B’s assets transfer:

    

    1. Party
A agrees to transfer Party B’s (a subsidiary of Party A) entire tangible assets
and 22 approved drug numbers to Party C and Party C agrees to purchase. The
total tangible assets include manufactory buildings, lands, office buildings,
equipments and inventories, etc. Actual contents should be based on Yan Hua Da
Hui Ping Zi No.30 (2008) appraisal report issued by Yantai Huada Certified
Public Accountants, Ltd. on September 28, 2008. Items with variations occurred
subsequent to the date of the appraisal, August 31, 2008, will be determined by
the actual transferred amounts (except manufactory buildings, land, office
buildings and other important facilities shall not have any variations
incurred); the differences will be added or subtracted from original amounts in
the appraisal report after negotiations among
three parties.

    

    2. Party
A and Party B shall assist Party C to apply to Shandong Province Food and
Drug Administration for transferring the ownership of the 22 approved drug
numbers to Party C, and Party C shall be responsible for related transactional
fees. If the ownership of the 22 approved drug numbers referenced above cannot
be transferred to Party C, Party C has the right to cancel this transfer
contract and requests Party A and Party B to refund acquisition payments and
related transactional fees made.

    

    3. Party
A and Party B shall assist Party C to transfer the ownership of the
property title certificate and land title certificate referenced above to Party
C and Party C shall be responsible for related transactional fees. If the
ownership of the property title certificate and land title certificate
referenced above cannot be transferred to Party C, Party C has the right to
cancel this transfer contract and requests Party A and Party B to refund
acquisition payments and related transactional fees made.

    

    4. Party
A and Party B shall guarantee that there has been no signed agreement or
contract with any creditors to restrict the assets transfer referenced above.
The assets referenced above have not been used as collaterals and the ownerships
of the assets to be transferred are clear.

    

    5. Except
for tangible assets and the approved 22 drug numbers referenced above, all of
Party B’s creditor’s or obligor’s rights and obligations prior to the
official handover shall be shared and divided between Party A and Party B. After
the official handover, Party B shall apply to business bureau to dissolve itself
as soon as possible. 

    

    
      
         

      

      
         

        
          

        

      

      
         

      

       

    

    6.
Arrangement of Party B's existing staffs:

    

    a. Prior
to the official handover, Party A and Party B shall organize and hold an
employees and workers meeting to pass relevant staff arrangements; the staff
arrangements should be accepted by relevant government departments.

    

    b. Party
B’s staff will be selectively employed by Party C. Party A will be
responsible for arrangements for staff not employed by Party C, Party A and
Party B will burden the related arrangement costs.

    

    c. The
work status of staff employed by Party C will be released from state owned
status, and Party A and Party B shall be responsible for the staff’s related
social insurance costs prior to the employment by Party C, and Party C
shall be responsible for the costs after the employment by Party C.

    

    7. Assets
transfer prices:

    

    After
negotiations, all three parties confirm the transfer price for all Party B’s
tangible assets and 22 approved drug numbers is 110 million RMB.

    

    8. Assets
transfer payment term:

    

    After the
provincial State-owned Assets Administration Department approves and consents
for the assets transfer and within one month of all three parties’ ( Party A,
Party B and Party C) completion of assets handover, Party C shall pay Party A an
onetime payment of 20 million RMB in cash. Another 46 million RMB (forty six
million Renminbi) will be paid after the ownership of the approval drug numbers
changed to Party C. The remaining 44 million RMB will be paid by Party C’s
shares, calculated using 10 U.S. dollars per share with an exchange rate of
6.836, totaling 643,651 shares. Shares will be issued within one year after the
signed contract date to Party A’s designated organizations or
individuals.

    

    9.
Specific handover date is scheduled to be February 5, 2009, presence of all
three parties are required at the time of the handover. The transferred
contents include but not limit to:

    

    a.
Property title certificate and land title certificate of the transferred
assets;

    b. Related
equipment repair and maintenance documentation;

    c. Related
manufacture approvals and licenses of the 22 drugs;

    d.
Related legal documents for all transferred assets.

    

    At the
time of handover, Party B shall provide the documents referenced above to Party
C and representatives of all three parties should sign off on the handover
documents.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    10. After
this agreement takes effective, senior management of Hongrui guarantees not to
manufacture or sale similar pharmaceutical products that Party C manufactures
within three years, senior management of Hongrui shall not contact Party B’s
current customers with improper intention.

    

    11.
Matters not concluded by this agreement are to be negotiated by all three
parties and the agreed-upon written terms will carry the equal legal
enforceability as this agreement.

    

    12. This
agreement has six copies. The copies become effective after the copies are
signed and sealed by all parties and the provincial State-owned Assets
Administration Department approves and consents for the assets transfer. Each of
the three parties will hold two copies.

    

    13. Dissensions occurred during the performance of this
agreement will be resolved by parties’ negotiations. If a resolution cannot be
reached, it shall be referred to and judged by Laiyang Municipal People’s
Court.

    

    Party A: Shandong Traditional
Chinese Medicine College (Seal)

    Legal
Representative:

    Date:
January 23, 2009

    

    

    

    Party B: The Traditional
Chinese Medicine College of Shandong Hongrui Pharmaceutical Factory
(Seal)

    Legal
Representative:

    Date:
January 23, 2009

    

    

    

    Party C: Laiyang Jiangbo
Pharmaceutical Co., Ltd.(Seal)

    Legal
Representative:

    Date:
January 23, 2009

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}]]